Canada In Vitro Diagnostics Market Outlook to 2017 – Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Publisher Name :
Date: 18-Jan-2012
No. of pages: 234

GlobalData’s new report, “Canada In Vitro Diagnostics Market Outlook to 2017 – Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Canada In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

  • Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
  • Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
  • 2010 company shares and distribution shares data for each of the seven market categories.
  • Global corporate-level profiles of key companies operating within the Canada In Vitro Diagnosticsmarket.
  • Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Canada In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Canada In Vitro Diagnostics Market Outlook to 2017 – Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 What is This Report About?

3 In Vitro Diagnostics In Canada

3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
3.3 In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2010
3.4 In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010
3.5 In Vitro Diagnostics, Canada, Company share (2009-2010)

4 Clinical Chemistry In Canada

4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, Canada, Revenue Mix ($m), 2010
4.3 Clinical Chemistry Market, Canada, Segment Contribution (%), 2010
4.4 Clinical Chemistry Overall Revenue (2003-2017)
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017)
4.4.2 Urine Analysis Revenue (2003-2017)
4.5 Clinical Chemistry Distribution Share (2009-2010)
4.6 Clinical Chemistry, Canada, Company share (2009-2010)

5 Genetic Testing In Canada

5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, Canada, Revenue Mix ($m), 2010
5.3 Genetic Testing Market, Canada, Segment Contribution (%), 2010
5.4 Genetic Testing Overall Revenue (2003-2017)
5.5 Genetic Testing Distribution Share (2009-2010)
5.6 Genetic Testing, Canada, Company share (2009-2010)

6 Haematology In Canada

6.1 Haematology, Market Segmentation
6.2 Haematology Market, Canada, Revenue Mix ($m), 2010
6.3 Haematology Market, Canada, Segment Contribution (%), 2010
6.4 Haematology Overall Revenue (2003-2017)
6.4.1 Haematology Reagents Revenue (2003-2017)
6.4.2 Immunohaematology Revenue (2003-2017)
6.4.3 Haemostasis Revenue (2003-2017)
6.4.4 Haematology Rapid Tests Revenue (2003-2017)
6.4.5 Haematology Cell Counters Revenue (2003-2017)
6.5 Haematology Distribution Share (2009-2010)
6.6 Haematology, Canada, Company share (2009-2010)

7 Histology And Cytology In Canada

7.1 Histology And Cytology, Market Segmentation
7.2 Histology And Cytology Market, Canada, Revenue Mix ($m), 2010
7.3 Histology And Cytology Market, Canada, Segment Contribution (%), 2010
7.4 Histology And Cytology Overall Revenue (2003-2017)
7.5 Histology And Cytology Distribution Share (2009-2010)
7.6 Histology And Cytology, Canada, Company share (2009-2010)

8 Immuno Chemistry In Canada

8.1 Immuno Chemistry Market, Canada, Revenue Mix ($m), 2010
8.2 Immuno Chemistry Market, Canada, Segment Contribution (%), 2010
8.3 Immuno Chemistry Overall Revenue (2003-2017)
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017)
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017)
8.3.3 Endocrinology Tests Revenue (2003-2017)
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017)
8.3.5 Immunochemistry Analyzers Revenue (2003-2017)
8.4 Immuno Chemistry Distribution Share (2009-2010)
8.5 Immuno Chemistry, Canada, Company share (2009-2010)

9 Infectious Immunology In Canada

9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, Canada, Revenue Mix ($m), 2010
9.3 Infectious Immunology Market, Canada, Segment Contribution (%), 2010
9.4 Infectious Immunology Overall Revenue (2003-2017)
9.5 Infectious Immunology Distribution Share (2009-2010)
9.6 Infectious Immunology, Canada, Company share (2009-2010)

10 Microbiology Culture In Canada

10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, Canada, Revenue Mix ($m), 2010
10.3 Microbiology Culture Market, Canada, Segment Contribution (%), 2010
10.4 Microbiology Culture Overall Revenue (2003-2017)
10.4.1 Microbiology Analyzers Revenue (2003-2017)
10.5 Microbiology Culture Distribution Share (2009-2010)
10.6 Microbiology Culture, Canada, Company share (2009-2010)

11 Overview of Key Companies in Canada In Vitro Diagnostics Market

11.1 Siemens Healthcare
11.1.1 Company Overview
11.1.2 Share in the Canada In Vitro Diagnostics Market
11.2 Abbott Laboratories
11.2.1 Company Overview
11.2.2 Share in the Canada In Vitro Diagnostics Market
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 Company Overview
11.3.2 Share in the Canada In Vitro Diagnostics Market
11.4 Beckman Coulter, Inc.
11.4.1 Company Overview
11.4.2 Share in the Canada In Vitro Diagnostics Market
11.5 Ortho-Clinical Diagnostics Inc.
11.5.1 Company Overview
11.5.2 Share in the Canada In Vitro Diagnostics Market
11.6 bioMerieux S.A.
11.6.1 Company Overview
11.6.2 Share in the Canada In Vitro Diagnostics Market
11.7 Becton, Dickinson and Company
11.7.1 Company Overview
11.8 Bio-Rad Laboratories, Inc.
11.8.1 Company Overview
11.9 Biomedica Diagnostics Inc.
11.9.1 Company Overview
11.10 Sysmex Corporation
11.10.1 Company Overview
11.11 Qiagen N.V.
11.11.1 Company Overview
11.12 Immucor, Inc.
11.12.1 Company Overview
11.13 Alere Inc.
11.13.1 Company Overview
11.14 Gen-Probe Incorporated
11.14.1 Company Overview
11.15 DiaSorin S.p.A
11.15.1 Company Overview
11.16 Thermo Fisher Scientific Inc.
11.16.1 Company Overview
11.17 Phadia AB
11.17.1 Company Overview
11.18 Hologic, Inc.
11.18.1 Company Overview
11.19 Grifols, S.A.
11.19.1 Company Overview
11.20 Life Technologies Corporation
11.20.1 Company Overview
11.21 HORIBA, Ltd.
11.21.1 Company Overview
11.22 PerkinElmer, Inc.
11.22.1 Company Overview

12 In Vitro Diagnostics Market Pipeline Products

12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology And Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products

13 Financial Deals Landscape

13.1 Merger
13.1.1 Transonic Systems Merges with Scisense
13.2 Acquisition
13.2.1 Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies
13.2.2 OraSure Technologies Completes Acquisition Of DNA Genotek
13.2.3 Trinity Biotech Acquires Phoenix Bio-Tech
13.3 Partnerships
13.3.1 Sony DADC Enters Into Co-Development Agreement With Axela
13.3.2 Genome British Columbia Enters Into Co-Development Agreement With Genome Canada
13.3.3 WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
13.3.4 Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics
13.3.5 Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada
13.3.6 Warnex Enters Into Licensing Agreement With Sorenson Forensics
13.3.7 Roche Enters Into Distribution Agreement With PerkinElmer
13.3.8 Pronexus Enters Into Technology Integration Agreement With RealityCorp
13.3.9 Carl Zeiss Enters Into Licensing Agreement With Prior Scientific
13.3.10 Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical
13.3.11 Signal Genetics Enters Into Research And Development Agreement With DiagnoCure
13.3.12 Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics
13.3.13 Mitomics Enters Into Licensing Agreement With QDx Pathology Services
13.3.14 Biofortuna Enters Into Distribution Agreement With Abbott
13.3.15 CML HealthCare Enters Into Licensing Agreement With Phenomenome Discoveries
13.3.16 Magellan BioScience Enters Into An Agreement With miacom diagnostics
13.3.17 Affymetrix Enters Into Distribution Agreement With Thermo Fisher

14 Recent Developments

14.1 Strategy and Business Planning
14.1.1 Dec 20, 2011: Warnex To Sell Analytical Services Division
14.1.2 Nov 30, 2011: SQI Diagnostics Announces Realignment Of Business And Reductions In Operating Expenses To Better Serve Its IVD And CustomPlex Businesses
14.1.3 Oct 04, 2011: Roche To Expand Coagulation Testing Portfolio, Develop New Systems For Diagnostic Laboratories In US And Canada By 2014
14.1.4 May 26, 2011: New England Biolabs Opens New Subsidiary Office In France
14.1.5 Mar 14, 2011: Pacgen Announces Corporate Transformation
14.2 Legal and Regulatory
14.2.1 Feb 24, 2011: Med Biogene Charged With Fraud and Precision Therapeutics Charged With Tortious Interference In Amended Complaint by Signal Genetics
14.3 Government and Public Interest
14.3.1 Dec 21, 2011: Miraculins Successfully Passes Critical ISO 13485 Certification Audit
14.3.2 Oct 05, 2011: Norgen Biotek Achieves Accreditation To ISO 15189:2007 For Molecular Diagnostic Testing And Clinical Trials
14.3.3 Sep 21, 2011: Aeterna Zentaris To Present At Sixth Annual JMP Securities Healthcare Conference
14.3.4 Aug 02, 2011: Noninvasive Fecal Occult Blood Test Effective Screen For Lower GI Tract Lesions: Study
14.3.5 Jul 28, 2011: Verisante Obtains ISO Certification Of Quality Management System For Medical Device Manufacturing
14.3.6 Jul 04, 2011: UBC's Megapixel DNA Replication Technology Promises Faster, More Precise Diagnostics
14.3.7 Jun 16, 2011: Researchers At Queen's University Develop First Diagnostic Test For Hereditary Children's Disease
14.4 Product News
14.4.1 Dec 19, 2011: British Columbia Cancer Agency Joins Illumina Genome Network
14.4.2 Oct 12, 2011: Affymetrix Releases Axiom Genome-Wide Pan-African Array
14.4.3 Oct 12, 2011: GeneDx Unveils XomeDx Test To Identify Rare Inherited Diseases
14.4.4 Oct 12, 2011: NanoString Launches Second Generation nCounter Analysis System
14.4.5 Oct 11, 2011: RainDance Technologies Launches ThunderStorm System At 12th ICHG In Montreal, Canada
14.4.6 Aug 31, 2011: CaridianBCT Launches Mononuclear Cell Collection Protocol For Spectra Optia Apheresis System In Canada
14.4.7 Aug 30, 2011: Aeterna Zentaris Announces Favorable Top-Line Results Of Completed Phase III Study On AEZS-130 As First Oral Diagnostic Test For Adult Growth Hormone Deficiency
14.4.8 Aug 22, 2011: Gen-Probe Receives Canadian Regulatory Clearance For PANTHER System
14.4.9 Aug 18, 2011: RPS Receives Health Canada Approval For RPS InflammaDry Detector
14.4.10 Jul 15, 2011: Sentinel Principle Used To Discover Blood Based Biomarkers To Predict Risk Of Liver Cancer From Patients With Chronic Hepatitis: GeneNews
14.4.11 Jul 06, 2011: Axial Biotech Signs Agreement With Shriners Hospital for Children To Provide SCOLISCORE AIS Prognostic Test
14.4.12 May 06, 2011: DiagnoCure To Present Previstage GCC Test At ASCRS In Canada
14.4.13 Feb 22, 2011: CardioGenics Receives Canadian Patent For QL Care Analyzer Core Technology
14.4.14 Feb 08, 2011: PinPointe Receives FDA Approval For PinPointe FootLaser In Canada

15 Appendix

15.1 Definitions of Markets Covered in the Report
15.1.1 In Vitro Diagnostics
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 GlobalData Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer

List Of Tables

Table 1: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
Table 2: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010
Table 3: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2003-2017
Table 4: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 5: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 6: In Vitro Diagnostics, Canada, Company share by Revenue ($m), USD Actual, 2009-2010
Table 7: Clinical Chemistry Market, Canada, Segment Contribution (%), 2010
Table 8: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 9: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 10: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 11: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 12: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 13: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 14: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 15: Clinical Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 16: Genetic Testing Market, Canada, Segment Contribution (%), 2010
Table 17: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 18: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 19: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 20: Genetic Testing, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 21: Haematology Market, Canada, Segment Contribution (%), 2010
Table 22: Haematology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 23: Haematology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 24: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 25: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 26: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 27: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 28: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 29: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 30: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 31: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 32: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 33: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 34: Haematology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 35: Haematology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 36: Histology And Cytology Market, Canada, Segment Contribution (%), 2010
Table 37: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 38: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 39: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 40: Histology And Cytology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 41: Immuno Chemistry Market, Canada, Segment Contribution (%), 2010
Table 42: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 43: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 44: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 45: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 46: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 47: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 48: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 49: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 50: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 51: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 52: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 53: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 54: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 55: Immuno Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 56: Infectious Immunology Market, Canada, Segment Contribution (%), 2010
Table 57: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 58: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 59: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 60: Infectious Immunology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 61: Microbiology Culture Market, Canada, Segment Contribution (%), 2010
Table 62: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 63: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 64: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 65: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 66: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 67: Microbiology Culture, Canada, Company share by Revenue ($m), USD Actual 2009-2010
Table 68: Clinical Chemisty Market Pipeline Products
Table 69: Immuno Chemistry Market Pipeline Products
Table 70: Haematology Market Pipeline Products
Table 71: Infectious Immunology Market Pipeline Products
Table 72: Microbiology Culture Market Pipeline Products
Table 73: Histology And Cytology Market Pipeline Products
Table 74: Genetic Testing Market Pipeline Products
Table 75: Transonic Systems Merges With Scisense
Table 76: Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies
Table 77: OraSure Technologies Completes Acquisition Of DNA Genotek
Table 78: Trinity Biotech Acquires Phoenix Bio-Tech
Table 79: Sony DADC Enters Into Co-Development Agreement With Axela
Table 80: Genome British Columbia Enters Into Co-Development Agreement With Genome Canada
Table 81: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
Table 82: Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics
Table 83: Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada
Table 84: Warnex Enters Into Licensing Agreement With Sorenson Forensics
Table 85: Roche Enters Into Distribution Agreement With PerkinElmer
Table 86: Pronexus Enters Into Technology Integration Agreement With RealityCorp
Table 87: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific
Table 88: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical
Table 89: Signal Genetics Enters Into Research And Development Agreement With DiagnoCure
Table 90: Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics
Table 91: Mitomics Enters Into Licensing Agreement With QDx Pathology Services
Table 92: Biofortuna Enters Into Distribution Agreement With Abbott
Table 93: CML HealthCare Enters Into Licensing Agreement With Phenomenome Discoveries
Table 94: Magellan BioScience Enters Into An Agreement With miacom diagnostics
Table 95: Affymetrix Enters Into Distribution Agreement With Thermo Fisher
Table 96: USD to Local Currency, Canada, Average Actual Rate 2003-2010

List Of Figures

Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
Figure 3: In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2010
Figure 4: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010
Figure 5: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2003-2017
Figure 6: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 8: In Vitro Diagnostics, Canada, Company share (%), 2010
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, Canada, Revenue Mix ($m), 2010
Figure 11: Clinical Chemistry Market, Canada, Segment Contribution (%), 2010
Figure 12: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 13: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 14: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 15: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 16: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 17: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 18: Clinical Chemistry, Canada, Company share (%), 2010
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, Canada, Revenue Mix ($m), 2010
Figure 21: Genetic Testing Market, Canada, Segment Contribution (%), 2010
Figure 22: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 23: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 24: Genetic Testing, Canada, Company share (%), 2010
Figure 25: Haematology, Market Segmentation
Figure 26: Haematology Market, Canada, Revenue Mix ($m), 2010
Figure 27: Haematology Market, Canada, Segment Contribution (%), 2010
Figure 28: Haematology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 29: Haematology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 30: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 31: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 32: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 33: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 34: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 35: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 36: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 37: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 38: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 39: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 40: Haematology, Canada, Company share (%), 2010
Figure 41: Histology And Cytology, Market Segmentation
Figure 42: Histology And Cytology Market, Canada, Revenue Mix ($m), 2010
Figure 43: Histology And Cytology Market, Canada, Segment Contribution (%), 2010
Figure 44: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 45: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 46: Histology And Cytology, Canada, Company share (%), 2010
Figure 47: Immuno Chemistry Market, Canada, Revenue Mix ($m), 2010
Figure 48: Immuno Chemistry Market, Canada, Segment Contribution (%), 2010
Figure 49: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 50: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 51: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 52: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 53: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 54: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 55: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 56: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 57: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 58: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 59: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 60: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 61: Immuno Chemistry, Canada, Company share (%), 2010
Figure 62: Infectious Immunology, Market Segmentation
Figure 63: Infectious Immunology Market, Canada, Revenue Mix ($m), 2010
Figure 64: Infectious Immunology Market, Canada, Segment Contribution (%), 2010
Figure 65: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 66: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 67: Infectious Immunology, Canada, Company share (%), 2010
Figure 68: Microbiology Culture, Market Segmentation
Figure 69: Microbiology Culture Market, Canada, Revenue Mix ($m), 2010
Figure 70: Microbiology Culture Market, Canada, Segment Contribution (%), 2010
Figure 71: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 72: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 73: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 74: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 75: Microbiology Culture, Canada, Company share (%), 2010
Figure 76: Siemens Healthcare, Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 77: Abbott Laboratories, Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 78: F. Hoffmann-La Roche Ltd., Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 79: Beckman Coulter, Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2010
Figure 81: bioMerieux S.A., Company Share (%),Canada In Vitro Diagnostics Market, 2010

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • 2014-2018 Point-of-Care/POC Clinical Chemistry and Immunodiagnostic Testing: Physician Offices, Emergency Rooms, Operating Suites, ICUs/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers–Supplier Shares, Country Forecasts, Emerging Technologies, Competitive Strategies
    Published: 12-Nov-2014        Price: US $8500 Onwards        Pages: 500
    "New Frontiers in Point-of-Care/POC Clinical Chemistry and Immunodiagnostic Testing: Business Challenges, Emerging Technologies, Competitive Landscape" is Venture Planning Group's new report, which provides comprehensive analysis of the POC clinical chemistry markets, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Rationale The growing economic pressures on hos......
  • 2014-2018 US Point-of-Care Clinical Chemistry Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers– Supplier Shares, Country Forecasts, Emerging Technologies, Competitive Strategies
    Published: 12-Nov-2014        Price: US $5500 Onwards        Pages: 373
    This new 373-page report from Venture Planning Group contains 61 tables, and provides a comprehensive analysis of the POC clinical chemistry market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC clinical chemistry market. Rationale ......
  • Future Horizons and Growth Strategies in the Global Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $8500 Onwards        Pages: 313
    This new 313-page report from Venture Planning Group contains 83 tables and provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin Carbamazepine Cyclosporin Digoxin Everolimus Gentamicin Levetiracet......
  • Future Horizons and Growth Strategies in the European Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $6500 Onwards        Pages: 291
    This new 291-page report from Venture Planning Group provides a comprehensive analysis of the European therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Pr......
  • Future Horizons and Growth Strategies in the French Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $2450 Onwards        Pages: 247
    This new 247-page report from Venture Planning Group provides a comprehensive analysis of the French therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Proc......
  • Future Horizons and Growth Strategies in the German Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $2450 Onwards        Pages: 249
    This new 249-page report from Venture Planning Group provides a comprehensive analysis of the German therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Proc......
  • Future Horizons and Growth Strategies in the Italian Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $2450 Onwards        Pages: 247
    This new 247-page report from Venture Planning Group provides a comprehensive analysis of the Italian therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Pro......
  • Future Horizons and Growth Strategies in the Japanese Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $2750 Onwards        Pages: 247
    This new 247-page report from Venture Planning Group provides a comprehensive analysis of the Japanese therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Pr......
  • Future Horizons and Growth Strategies in the Spanish Therapeutic Drug Monitoring (TDM) Market 2014: Supplier Shares and Country Forecasts
    Published: 26-Aug-2014        Price: US $2450 Onwards        Pages: 249
    This new 249-page report from Venture Planning Group provides a comprehensive analysis of the Spanish therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Pro......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs